This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jung, M. Articles by Dritschilo, A. Search for Related Content PubMed PubMed Citation Articles by Jung, M. Articles by Dritschilo, A.

¹ Department of Radiation Medicine, Georgetown University Medical Center, Washington, District of Columbia and ² Research and Development, Best Medical Industries, Inc., Springfield, Virginia

Requests for reprints: Mira Jung, Department of Radiation Medicine, Division of Radiation Research, Georgetown University Medical Center, Research Building, Suite E211, Box 571482, Washington, DC 20057-1482. Phone: 202-687-8352; Fax: 202-687-7529. E-mail: jungm{at}georgetown.edu

Gene therapy is a promising approach for the treatment of cancers. Strategies for gene vector delivery include systemic and local-regional approaches. Intratumoral delivery of vectors has generally employed direct injections into single or multiple locations throughout the tumor volume. However, this approach leads to nonuniform distributions of reagents within tumors and becomes cumbersome as the required number of injections is increased. We have investigated the effectiveness of an interstitial plasmid gene delivery based on using tiny metallic seeds (GeneSeeds) analogous to technology used for brachytherapy. Feasibility for interstitial use of GeneSeeds was demonstrated expressing reporter plasmids (green fluorescence protein or ß-galactosidase) in human xenograft prostate tumors. Immunohistochemical analysis confirmed effective interstitial delivery, vector expression, and distributions of reporter genes within tumors. Applicability of GeneSeeds for delivery of radiosensitizing cytokines was examined by generating a cytokine [tumor necrosis factor- (TNF-)] expressing vector under the cytomegaloviral promoter and interstitially implanting GeneSeeds with this vector into prostate cancer tumors. TNF- protein expression was observed around the ends of seeds and decreasing in an exponential gradient as a function of distance. The expression of TNF- resulted in tumor growth delay of a human prostate cancer xenograft. These results demonstrate the feasibility of applying interstitial delivery of gene expressing vectors for the treatment of human cancers.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/ 5/03; revised 2/10/04; accepted 4/ 2/04.